Table 5 Predictors of QoL in stepwise multivariable linear regression analyses
EQ-5D VAS | WHO-5 | SGRQ | UCSD | |
|---|---|---|---|---|
Beta 95% CI p value | Beta 95% CI p value | Beta 95% CI p value | Beta 95% CI p value | |
Age | 0.28 0.05; 0.52 0.018 | |||
Disease duration in months | 0.07 0.02; 0.12 0.010 | |||
GAP index | ||||
Stage I | (ref) | |||
Stage II | −5.02 −10.78; 0.74 0.087 | |||
Stage III | −12.24 −19.71; −4.78 0.001 | |||
Physician’s overall judgment | ||||
Stable disease | (ref) | (ref) | (ref) | |
Slow progression | −5.46 −12.48; 1.55 0.126 | −0.42 −1.61; 0.76 0.484 | 2.59 −3.36; 8.54 0.392 | |
Rapid progression | −15.28 −25.42; −5.14 0.003 | −2.74 −4.73; −0.75 0.007 | 9.06 1.35; 16.76 0.021 | |
No judgement possible | −5.43 −12.72; 1.86 0.144 | −0.43 −1.68; 0.81 0.495 | 2.40 −3.98; 8.77 0.460 | |
Long-term oxygen therapy | −14.31 −20.66; −7.95 <0.001 | −3.20 −4.32; −2.08 <0.001 | 7.42 1.74; 13.10 0.011 | 22.99 13.50; 32.48 <0.001 |
NYHA functional class | ||||
I | (ref) | (ref) | (ref) | |
II | −8.52 −15.67; −1.37 0.020 | 12.85 5.76; 19.94 <0.001 | 15.78 7.55; 24.01 <0.001 | |
III | −7.40 −15.36; 0.55 0.068 | 21.05 13.06; 29.04 <0.001 | 28.96 18.96; 38.95 <0.001 | |
IV | −24.87 −37.41; −12.32 <0.001 | 29.63 19.32; 39.94 <0.001 | 38.49 22.48; 54.51 <0.001 | |
FVC %pred | 0.04 0.01; 0.07 0.006 | −0.21 −0.36; −0.06 0.005 | −0.33 −0.57; −0.09 <0.001 | |